[Correspondence] Neoadjuvant chemotherapy for early breast cancer

We congratulate the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) on their important meta-analysis.1 Neoadjuvant chemotherapy (NACT) has become an important tool and strategy for patients with breast cancer. Although NACT was traditionally used in patients with locally advanced breast cancer, with the aim of downstaging and achieving operability, monitoring treatment response for prognostic purposes and for risk stratification has become routine in current practice.

Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Authors: David Krug, Sibylle Loibl Tags: Correspondence Source Type: research